{"id":"tiotropium-bromide-tio","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dry mouth"},{"rate":"2-5","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"1-2","effect":"Urinary retention"},{"rate":"2-4","effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL3545181","moleculeType":"Small molecule","molecularWeight":"490.44"},"_dailymed":{"setId":"7b656b14-fcaa-2741-f6f0-e0be48971c02","title":"SPIRIVA RESPIMAT (TIOTROPIUM BROMIDE INHALATION SPRAY) SPRAY, METERED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium binds to muscarinic M3 receptors on bronchial smooth muscle, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. The drug is inhaled once daily and provides 24-hour bronchodilation, making it a maintenance therapy for chronic obstructive pulmonary disease.","oneSentence":"Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks M3 muscarinic receptors on airway smooth muscle to produce sustained bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:09:26.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Asthma (in combination with inhaled corticosteroids)"}]},"trialDetails":[{"nctId":"NCT05393245","phase":"","title":"Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19467},{"nctId":"NCT05402020","phase":"","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17018},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11316},{"nctId":"NCT04926233","phase":"","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1371146},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT04402515","phase":"","title":"Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2021-10-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT02850978","phase":"","title":"Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1335},{"nctId":"NCT03376295","phase":"","title":"Comparative Effectiveness of COPD Treatments","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3954},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT01040403","phase":"PHASE2","title":"Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":233},{"nctId":"NCT00168831","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1007},{"nctId":"NCT00168844","phase":"PHASE3","title":"Tiotropium / Respimat One-Year Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":983},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Spriva®"],"phase":"marketed","status":"active","brandName":"tiotropium bromide (TIO)","genericName":"tiotropium bromide (TIO)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium bromide (TIO) is used to treat Chronic Obstructive Pulmonary Disease (COPD). It is typically administered in combination with other medications, such as olodaterol, for maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}